23andMe hit with class-action lawsuit; Glass Dx tools with trained honeybees help spot cancer;

> 23andMe now faces a class-action lawsuit claiming the company misled customers by selling genetic tests with no real scientific value. Story

> Roche ($RHHBY) is launching a new lab instrument for high-volume processing of molecular diagnostic samples. Item

> A University of Toronto spinout nailed down $18.8 million in a Series B financing that will help advance its rapid-use molecular diagnostic technology in the U.S. Story

> A new blood test can detect a person's risk of infection from a drop of blood within minutes, according to a study published in the journal Technology. Story

> A Portuguese designer has developed a series of glass diagnostic tools that use trained honeybees to determine if a patient has cancer. Story

Suggested Articles

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.

Janssen tapped Resolution Bioscience to develop a companion diagnostic for Zejula in patients with metastatic castration-resistant prostate cancer.